HRS-4642 plus other therapies for pancreatic cancer
Part of Cancer clinical trials.
This study tests an experimental drug (HRS-4642) combined with other cancer treatments for people with advanced pancreatic cancer that has spread or cannot be removed. The goal is to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have pancreatic duct adenocarcinoma that has spread or cannot be removed by surgery
- You are well enough to be up and about (ECOG 0 or 1)
- You have a tumor sample (from a past biopsy or a new one) available for testing
- You do not have untreated cancer spread to the brain or active lung inflammation
- You have a tumor that can be measured on scans (like CT or MRI)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted immune therapy (Adebrelimab) with three chemotherapy drugs for people with metastatic pancreatic cancer who haven't had any treatment yet. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests a combination of two drugs (HRS-4642 and adebrelimab) for people with advanced pancreatic cancer that has not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow the disease.
This trial tests a new drug, HRS-4642, combined with a two-drug chemotherapy (nab-paclitaxel and gemcitabine) for people with locally advanced pancreatic cancer that has not spread. The goal is to shrink the tumor enough so it can be surgically removed.
This trial tests a new drug combination for pancreatic cancer that has not been treated before. It may help shrink tumors or make surgery possible for people with advanced or borderline resectable disease.
This trial tests a new targeted drug (HRS-4642) combined with nimotuzumab and chemotherapy for people with advanced pancreatic cancer that has a specific gene change called KRAS G12D. It's for those who haven't had treatment for advanced disease yet.
This trial tests personalized therapies for people with advanced pancreatic cancer that has spread or cannot be removed. It aims to find the best treatment based on your tumor's unique features.
Hear when a new Locally Advanced or Metastatic Pancreatic Cancer With trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.